Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F21%3AN0000074" target="_blank" >RIV/00027162:_____/21:N0000074 - isvavai.cz</a>

Alternative codes found

RIV/60077344:_____/21:00555182

Result on the web

<a href="https://www.mdpi.com/1999-4915/13/5/912" target="_blank" >https://www.mdpi.com/1999-4915/13/5/912</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/v13050912" target="_blank" >10.3390/v13050912</a>

Result language

angličtina

Original language name

Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2

Original language description

Multiple outbreaks of epidemic and pandemic viral diseases have occurred in the last 20 years, including those caused by Ebola virus, Zika virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence or re-emergence of such diseases has revealed the deficiency in our pipeline for the discovery and development of antiviral drugs. One promising solution is the extensive library of antimicrobial peptides (AMPs) produced by all eukaryotic organisms. AMPs are widely known for their activity against bacteria, but many possess additional antifungal, antiparasitic, insecticidal, anticancer, or antiviral activities. AMPs could therefore be suitable as leads for the development of new peptide-based antiviral drugs. Sixty therapeutic peptides had been approved by the end of 2018, with at least another 150 in preclinical or clinical development. Peptides undergoing clinical trials include analogs, mimetics, and natural AMPs. The advantages of AMPs include novel mechanisms of action that hinder the evolution of resistance, low molecular weight, low toxicity toward human cells but high specificity and efficacy, the latter enhanced by the optimization of AMP sequences. In this opinion article, we summarize the evidence supporting the efficacy of antiviral AMPs and discuss their potential to treat emerging viral diseases including COVID-19.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

10607 - Virology

Project

<a href="/en/project/NV19-05-00457" target="_blank" >NV19-05-00457: Genetic predisposition to different clinical course and severity of tick-borne encephalitis</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Viruses

ISSN

1999-4915

e-ISSN

1999-4915

Volume of the periodical

13

Issue of the periodical within the volume

5

Country of publishing house

CH - SWITZERLAND

Number of pages

11

Pages from-to

—

UT code for WoS article

000654600000001

EID of the result in the Scopus database

2-s2.0-85106981267